Dose–response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Journal of Cerebral Blood Flow and Metabolism

• Publication date

  2019-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/0271678X18764773PMID 29537907PMCID PMC6681526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of Stroke Therapy Academic Industry Roundtable (STAIR) Guidelines on Peri-Anesthesia Care for Rat Models of Stroke: A Meta-Analysis Comparing the Years 2005 and 2015

  2017cited by this paper
• Current and future perspectives on the treatment of cerebral ischemia

  2017cited by this paper
• Thrombolytic Therapy in Wake-Up Stroke Patients

  2017cited by this paper
• Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.

  2017cited by this paper
• Role of interleukin‐10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury

  2017cited by this paper
• Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice

  2016cited by this paper
• Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association

  2016cited by this paper
• Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo

  2016cited by this paper
• Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence.

  2016cited by this paper
• Abstract 32: Direct Angiotensin II Type 2 Receptor Stimulation by Compound 21 Prevents Vascular Dementia

  2015cited by this paper
• Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke

  2015cited by this paper
• Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia.

  2015cited by this paper
• The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.

  2014cited by this paper
• Direct Angiotensin AT2 Receptor Stimulation Using a Novel AT2 Receptor Agonist, Compound 21, Evokes Neuroprotection in Conscious Hypertensive Rats

  2014cited by this paper
• Vascular change and opposing effects of the angiotensin type 2 receptor in a mouse model of vascular cognitive impairment

  2014cited by this paper
• Candesartan Reduces the Hemorrhage Associated with Delayed Tissue Plasminogen Activator Treatment in Rat Embolic Stroke

  2013cited by this paper
• Protective Effect of Carnosine on Subcortical Ischemic Vascular Dementia in Mice

  2012cited by this paper
• RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research

  2012cited by this paper
• Scientific Rigor Recommendations for Optimizing the Clinical Applicability of Translational Research.

  2012cited by this paper
• Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT₂ receptor agonist, to the striatum in rats.

  2011cited by this paper
• Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II

  2011cited by this paper
• Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors.

  2011cited by this paper
• Non-peptide AT2-receptor agonists.

  2011cited by this paper
• Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies

  2011cited by this paper
• A Mouse Model of Hemorrhagic Transformation by Delayed Tissue Plasminogen Activator Administration After In Situ Thromboembolic Stroke

  2011cited by this paper
• Stimulation of angiotensin AT2 receptors by the non‐peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats

  2010cited by this paper
• Reporting : The ARRIVE Guidelines for Reporting Animal Research

  2010cited by this paper
• Vascular Protection with Candesartan after Experimental Acute Stroke in Hypertensive Rats: A Dose-Response Study

  2008cited by this paper
• Tissue-type plasminogen activator as a therapeutic target in stroke

  2008cited by this paper
• Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage

  2006cited by this paper
• The role of vertebral and internal carotid artery disease in the pathogenesis of vertebrobasilar transient ischemic attacks

  2005cited by this paper
• Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat

  2005cited by this paper
• Working memory deficits in retinoid X receptor gamma-deficient mice.

  2005cited by this paper
• Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.

  2004cited by this paper
• Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation

  2004cited by this paper
• Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats

  2003cited by this paper
• Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke

  2002cited by this paper
• Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

  1998cited by this paper
• A rat model of focal embolic cerebral ischemia.

  1997cited by this paper
• 'Malignant' middle cerebral artery territory infarction : Clinical course and prognostic signs

  1996cited by this paper
• 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs.

  1996cited by this paper

• Enhancing glymphatic transport through angiotensin II type 2 receptor activation promotes neurological recovery after traumatic brain injury

  2025cites this paper
• Delayed Administration of an Angiotensin II Type 2 Receptor Agonist Promotes Functional Recovery of the Brain and Heart After Traumatic Brain Injury

  2024cites this paper
• Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke.

  2023cites this paper
• NPD1 Plus RvD1 Mediated Ischemic Stroke Penumbra Protection Increases Expression of Pro-homeostatic Microglial and Astrocyte Genes

  2023cites this paper
• Intra-arterial verapamil improves functional outcomes of thrombectomy in a preclinical model of extended hyperglycemic stroke

  2023cites this paper
• TREM2 mediates physical exercise-promoted neural functional recovery in rats with ischemic stroke via microglia-promoted white matter repair

  2023cites this paper
• The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target

  2022cites this paper
• Neuroprotection in Stroke—Focus on the Renin-Angiotensin System: A Systematic Review

  2022cites this paper
• Development and Testing of Thrombolytics in Stroke

  2021cites this paper
• Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA

  2021cites this paper
• Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke.

  2021cites this paper
• Compound 21, a Direct AT2R Agonist, Induces IL-10 and Inhibits Inflammation in Mice Following Traumatic Brain Injury

  2021cites this paper
• C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke

  2020cites this paper
• Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy

  2020cites this paper
• The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential

  2020cites this paper
• Optimized mouse model of embolic MCAO: From cerebral blood flow to neurological outcomes

  2020cites this paper
• Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double‐ blind pre‐clinical study

  2019cites this paper
• Delayed Administration of Angiotensin II Type 2 Receptor (AT2R) Agonist Compound 21 Prevents the Development of Post-stroke Cognitive Impairment in Diabetes Through the Modulation of Microglia Polarization

  2019cites this paper
• Angiotensin II Type 2 Receptor-Expressing Neurons in the Central Amygdala Influence Fear-Related Behavior.

  2019cites this paper
• Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.

  2019cites this paper
• Neuroprotection via AT2 receptor agonists in ischemic stroke.

  2018cites this paper
• RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial

  2018cites this paper